source
- Emerging Antibody-Drug Conjugates Target New Endometrial Cancer Antigens Beyond HER2Faculty members highlighted a growing interest in endometrial cancer therapies that go beyond the HER2 pathway. They noted that the field is expanding its focus to a broader set of molecular target…
- Cytokinetics' HCM drug shows positive trial results, potentially doubling market after Bristol Myers' setbackCytokinetics announced that its oral therapy for hypertrophic cardiomyopathy (HCM) achieved positive results in a pivotal trial targeting a different form of the disease. The data suggest the drug…